0000000000244019

AUTHOR

Yusuf Yilmaz

0000-0003-4518-5283

showing 6 related works from this author

Geographical similarity and differences in the burden and genetic predisposition of NAFLD

2022

: NAFLD has become a major public health problem for more than 2 decades with a growing prevalence in parallel with the epidemic of obesity and type 2 diabetes (T2D). The disease burden of NAFLD differs across geographical regions and ethnicities. Variations in prevalence of metabolic diseases, extent of urban-rural divide, dietary habits, lifestyles, and the prevalence of NAFLD risk and protective alleles can contribute to such differences. The rise in NAFLD has led to a remarkable increase in the number of cases of cirrhosis, hepatocellular carcinoma, hepatic decompensation, and liver-related mortality related to NAFLD. Moreover, NAFLD is associated with multiple extrahepatic manifestatio…

HepatologyNAFLD
researchProduct

Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes

2023

Background: We evaluated the diagnostic accuracy of simple non-invasive tests(NITs) in NAFLD patients with type 2 diabetes(T2D). Methods: This was an individual patient data meta-analysis of 1780 patients with biopsy-proven NAFLD and T2D. The index tests of interest were FIB-4, NAFLD Fibrosis Score(NFS), APRI, liver stiffness measurement(LSM) by vibration-controlled transient elastography(VCTE) and AGILE 3+. The target conditions were advanced fibrosis, nonalcoholic steatohepatitis(NASH) and fibrotic NASH(NASH plus F2-F4 fibrosis). The diagnostic performance of NITs individually or in sequential combination was assessed by area under receiver operating characteristic curve(AUROC) and by dec…

Hepatologynafld diabetes noninvasive fibrosis
researchProduct

Advancing the global public health agenda for NAFLD: a consensus statement

2021

Digital

medicine.medical_specialtyCivil societyDelphi methodMEDLINENashMULTIDISCIPLINARY APPROACHDiseaseLATIN-AMERICAN ASSOCIATIONMultidisciplinary approachQUALITY-OF-LIFENon-alcoholic Fatty Liver DiseaseEpidemiologyMedicineHumansHumans; Non-alcoholic Fatty Liver DiseasePOSITION STATEMENTBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.FATTY LIVER-DISEASEBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Hepatologybusiness.industryPublic healthGastroenterologyALCOHOLIC STEATOHEPATITISNONINVASIVE DIAGNOSISmedicine.diseaseObesityCARDIOVASCULAR-DISEASEPRACTICE GUIDELINESFamily medicinePRACTICAL APPROACHHuman medicinebusiness
researchProduct

Administrative Coding in Electronic Health Care Record‐Based Research of NAFLD: An Expert Panel Consensus Statement

2021

BACKGROUND AND AIMS: Electronic health record (EHR)-based research allows the capture of large amounts of data, which is necessary in nonalcoholic fatty liver disease (NAFLD), where the risk of clinical liver outcomes is generally low. The lack of consensus on which International Classification of Disease (ICD) codes should be used as exposures and outcomes limits comparability and generalizability of results across studies. We aimed to establish consensus among a panel of experts on ICD codes that could become the reference standard and provide guidance around common methodological issues.APPROACH AND RESULTS: Researchers with an interest in EHR-based NAFLD research were invited to collect…

0301 basic medicinemedicine.medical_specialtyFIBROSIS STAGEBiomedical ResearchConsensusClinical SciencesImmunologyDiseaseMedical Biochemistry and MetabolomicsDIAGNOSISVALIDATIONArticle03 medical and health sciences0302 clinical medicineClinical ResearchNon-alcoholic Fatty Liver DiseaseEpidemiologyHealth caremedicineElectronic Health RecordsHumansGeneralizability theoryALGORITHMFATTY LIVER-DISEASEStatement (computer science)Gastroenterology & HepatologyHepatologybusiness.industryMORTALITYComparabilityClinical CodingReference Standards3. Good healthGood Health and Well Being030104 developmental biology3121 General medicine internal medicine and other clinical medicineFamily medicineInclusion and exclusion criteria030211 gastroenterology & hepatologyPatient SafetybusinessPsychologyREAL-WORLDCoding (social sciences)Hepatology
researchProduct

A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

2020

The exclusion of other chronic liver diseases including “excess” alcohol intake has until now been necessary to establish a diagnosis of metabolic dysfunction-associated fatty liver disease (MAFLD). However, given our current understanding of the pathogenesis of MAFLD and its rising prevalence, “positive criteria” to diagnose the disease are required. In this work, a panel of international experts from 22 countries propose a new definition for the diagnosis of MAFLD that is both comprehensive and simple, and is independent of other liver diseases. The criteria are based on evidence of hepatic steatosis, in addition to one of the following three criteria, namely overweight/obesity, presence …

Liver Cirrhosis0301 basic medicineCirrhosisDiagnostic criteriaCirrhosis; Diabetes; Diagnostic criteria; MAFLD; Metabolic; NAFLD; Obesity; Steatohepatitis[SDV]Life Sciences [q-bio]HISTOLOGIC FEATURESPROGRESSIONDiseaseTerminology0302 clinical medicineMedicine10. No inequalitySteatohepatitisNONALCOHOLIC STEATOHEPATITISFatty liverHIGH BLOOD-PRESSUREDiabetesHEALTHY OBESE3. Good healthPREVALENCECausalityCirrhosisDisease Progression030211 gastroenterology & hepatologymedicine.medical_specialtyConsensusMAFLDDIAGNOSIS03 medical and health sciencesMetabolic DiseasesTerminology as TopicDiabetes mellitusNAFLDMANAGEMENTHumansObesityIntensive care medicineHepatologybusiness.industryType 2 Diabetes MellitusNATURAL-HISTORYmedicine.diseaseFatty LiverClinical trial030104 developmental biologyDiabetes Mellitus Type 2MetabolicSteatohepatitisbusiness
researchProduct

The case for simplifying and using absolute targets for viral hepatitis elimination goals

2021

The 69th World Health Assembly endorsed the Global Health Sector Strategy for Viral Hepatitis, embracing a goal to eliminate hepatitis infection as a public health threat by 2030. This was followed by the World Health Organization's (WHO) global targets for the care and management of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These announcements and targets were important in raising awareness and calling for action; however, tracking countries’ progress towards these elimination goals has provided insights to the limitations of these targets. The existing targets compare a country's progress relative to its 2015 values, penalizing countries who started their programmes …

ddc:616Carcinoma HepatocellularHepatologyHepatitis Viral Humanbusiness.industryLiver Neoplasmsddc:616.07medicine.diseaseWorld Health OrganizationVirologydigestive system diseasesGoalInfectious DiseasesAbsolute (philosophy)SDG 3 - Good Health and Well-beingVirologymedicineHumansViral hepatitisbusinessGoalsHuman
researchProduct